



**Proteomics International**

LABORATORIES LTD

**ASX Release**  
**3 November 2021**

**ASX code: PIQ**

## **Proteomics International awarded \$100,000 manufacturing funding**

- **\$100,000 funding to support manufacture of PromarkerD predictive test for diabetic kidney disease and other diagnostic tests in Western Australia**
- **Funding will be used to establish additional ISO 13485 quality control processes for manufacture of the immunoassay version of the PromarkerD test**
- **Awarded through the MTPConnect WA Life Sciences Innovation Hub**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has been awarded a \$100,000 voucher to support the manufacture of clinical diagnostic tests in Western Australia. The funding targets future local production of Proteomics International's PromarkerD blood test, the world's first predictive diagnostic test for diabetic kidney disease.

The funding was awarded for Proteomics International's project "Manufacturing the next generation *in vitro* diagnostic device to predict diabetic kidney disease", whereby the Company will establish WA based manufacturing quality control (QC) capability for PromarkerD. In doing so, this project will support the future large-scale manufacture of the PromarkerD test for Australia and the South-East Asia region.

Proteomics International managing director Dr Richard Lipscombe said *"Our company is in a unique position to be able to extend our recent ISO 13485-certified quality management system for manufacturing of medical devices [ASX: 4 April] to additional parts of the manufacturing process, specifically QC testing, by building on our laboratory's ISO 17025 accreditation and extensive experience in analytical services."*

Proteomics International recently announced two important strategic partnerships for the manufacture of the PromarkerD immunoassay and its key reagents in the Northern Hemisphere [ASX: 22 July, 11 August]. The project will also provide Proteomics International with capability to qualify these global supply chains to international manufacturing standards.

The funding is made possible through the MTPConnect WA Life Sciences Innovation Hub MTP (medical technology and pharmaceutical) Manufacturing Voucher Program and was announced yesterday by WA State Development, Jobs and Trade Minister Roger Cook MLA. The \$100,000 voucher will be matched dollar for dollar by the Company, with the project to be completed over a 9 month period.

Dr Richard Lipscombe added this new initiative looks to the future sales of PromarkerD in Australia and into South-East Asia. *"Ultimately, by enhancing our production capabilities, patients in the region will benefit as they will have easier access to the test."*

Establishing capability for manufacturing PromarkerD locally will also help launch future diagnostic tests under development by Proteomics International and potentially other companies, bringing more novel Australian medical devices to market in this expanding area.

*"Australian medical device companies who want to manufacture diagnostic tests of this kind currently have to partner with businesses overseas to meet globally-recognised standards. This project will build*

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

*expertise here in Western Australia, ensuring more Australian intellectual property remains onshore, creating speciality jobs, and attracting local and international talent,” said Dr Lipscombe.*

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

**About MTPConnect and the WA Life Sciences Innovation Hub ([www.mtpconnect.org.au](http://www.mtpconnect.org.au))**

Established in 2015 as an independent, not-for-profit organisation, MTPConnect is Australia’s Medical Technologies and Pharmaceuticals Industry Growth Centre, championing the growth of Australia’s vibrant MTP ecosystem.

The MTPConnect WA Life Sciences Innovation Hub is co-funded through the WA Government’s New Industries Fund and the University of Western Australia to accelerate economic growth and create new jobs and industries in Western Australia. The MTP Manufacturing Voucher Program is designed to boost medical products manufacturing in Western Australia.

**About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique ‘fingerprint’ of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud-based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: [www.PromarkerD.com/product](http://www.PromarkerD.com/product)

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)